M. Roach

发表

Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy.

David Beyer, Mack Roach, D. Beyer, 2002, International journal of radiation oncology, biology, physics.

Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience.

J. Kurhanewicz, M. Swanson, D. Vigneron, 2004, Radiology.

Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer.

J. Kurhanewicz, K. Shinohara, B. Pickett, 2004, International journal of radiation oncology, biology, physics.

Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer.

M. Roach, G. Sasso, J. Simpson, 2007, Neoplasia.

Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection.

C. McCulloch, J. Kurhanewicz, M. Roach, 2010, Radiology.

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

A. Markoe, K. Russell, H. Sandler, 2000, International journal of radiation oncology, biology, physics.

Computer-Assisted, Atlas-Based Segmentation for Target Volume Delineation in Whole Pelvic IMRT for Prostate Cancer

Ping Xia, Sue S Yom, I-Chow Hsu, 2013, Technology in cancer research & treatment.

Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.

Issam El-Naqa, Mack Roach, Charles Catton, 2007, International journal of radiation oncology, biology, physics.

Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC).

A H Russell, R. Komaki, L. Gaspar, 1998, International journal of radiation oncology, biology, physics.

Technique for implantation of fiducial markers in the prostate.

K. Shinohara, M. Roach, 2008, Urology.

A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).

D. Beyer, C. Catton, H. Sandler, 2017, International journal of radiation oncology, biology, physics.

Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).

A. Markoe, J. Earle, H. Sandler, 2002, International journal of radiation oncology, biology, physics.

Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.

J. Kurhanewicz, M. Roach, F. Coakley, 2012, Cancer treatment reviews.

Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.

P. Xia, C. Akazawa, M. Roach, 2006, International journal of radiation oncology, biology, physics.

Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.

J. Pouliot, I. Hsu, V. Weinberg, 2007, International journal of radiation oncology, biology, physics.

Salvage permanent perineal radioactive‐seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy

I. Hsu, K. Shinohara, J. Speight, 2009, BJU international.

Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.

I. Hsu, V. Weinberg, K. Shinohara, 2013, International journal of radiation oncology, biology, physics.

Predicting pathologic stage, nomograms, and clinical judgment: don't miss the forest for the trees!

M. Roach, 2009, International journal of radiation oncology, biology, physics.

Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials.

M. Roach, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.

H. Sandler, K. Bae, D. Taussky, 2008, Urology.

Progression free survival (PFS) after whole-pelvic (WP) vs. mini-pelvic (MP) or prostate only (PO) radiotherapy (RT): A subset analysis of RTOG 9413, a Phase III prospective randomized trial using neoadjuvant and concurrent (N&CHT)

Charles R. Thomas, R. Valicenti, M. Desilvio, 2004 .

Diagnostic Performance of 1.5 Tesla Endorectal MR Imaging and MR Spectroscopic Imaging for the Detection of Locally Recurrent Prostate Cancer after External Beam Radiation Therapy

J. Kurhanewicz, V. Weinberg, M. Roach, 2010 .

Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.

A. Kishan, R. Mehra, H. Sandler, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer.

W. Curran, M. Graham, J. Cox, 1992, Journal of the National Cancer Institute.

The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985).

W. Sause, C. Perez, M. Roach, 1992, International journal of radiation oncology, biology, physics.

The evolving role of pelvic radiation therapy.

M. Roach, T. Roberts, 2003, Seminars in radiation oncology.

An Analysis of Patients with Clinically Localized High‐Risk Prostate Carcinoma

V. Weinberg, Q. Le, M. Roach, 2000 .

Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions.

J. Speight, M. Roach, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy.

J. Pouliot, I. Hsu, J. Cunha, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

R. Socher, James Y. Zou, S. Yeung, 2022, npj Digital Medicine.

Efficacy of external beam radiotherapy compared to permanent prostate implant in treating low risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and PSA

J. Pouliot, J. Kurhanewicz, K. Shinohara, 2004 .

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.

A. Kishan, R. Mehra, H. Sandler, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials

Hanks, E. Horwitz, T. Pisansky, 2019 .

Understanding High-Dose, Ultra-High Dose-Rate and , Spatially Fractionated Radiotherapy.

C. N. Coleman, Sha X. Chang, S. Kalnicki, 2020, International journal of radiation oncology, biology, physics.

Do not count out external-beam radiation therapy for high-risk prostate cancer.

H. Sandler, J. Michalski, D. Hamstra, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.

S. Goldenberg, M. Roach, B. Davis, 2013, The Journal of urology.

Radical prostatectomy or external beam radiotherapy

M. Roach, 2002, Cancer.

Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study.

E. Perez, D. Gandara, M. Roach, 1991, International journal of radiation oncology, biology, physics.

Computer-Assisted, Atlas-Based Segmentation for Target Volume Delineation in Whole Pelvic IMRT for Prostate Cancer

I. Hsu, P. Xia, J. Speight, 2008, Technology in cancer research & treatment.

Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy

I. Hsu, Lijun Ma, A. Sahgal, 2011, Physics in medicine and biology.

Cautious optimism for extreme dose escalation in prostate cancer.

M. Roach, A. Chang, 2013, European urology.

Race and Prostate Cancer: What Do We Know?

M. Roach, C. D. Young, 2000 .

Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: results of RTOG 94-12.

W. Sause, J. Michalski, Srinivasan Vijayakumar, 1998, International journal of radiation oncology, biology, physics.

Dose Escalated External Beam Radiotherapy versus Neoadjuvant Androgen Deprivation Therapy and Conventional Dose External Beam Radiotherapy for Clinically Localized Prostate Cancer: Do we Need Both?

M. Roach, 2007, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Phase III radiation therapy oncology group (RTOG) trial 86-10 od androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate

D. Grignon, P. Rubin, W. Sause, 1998 .

Salvage Prostate Brachytherapy for Postradiation Local Failure

I. Hsu, M. Roach, G. Créhange, 2017 .

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer

M. Roach, R. Aggarwal, Harry J. Han, 2020, Therapeutic advances in medical oncology.

[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].

D. Grignon, W. Shipley, J. Cox, 2001 .

An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13

Charles R. Thomas, Christopher U. Jones, R. Valicenti, 2005 .

Contemporary results of permanent prostate seed implantation (PPI) versus conformal proton beam radiotherapy (CPBRT) to 79Gy

I. Hsu, V. Weinberg, K. Shinohara, 2005 .

Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406

A. Markoe, H. Sandler, J. Purdy, 2000 .

Sentinel lymph node imaging guided IMRT for prostate cancer: Individualized pelvic radiation therapy versus RTOG guidelines

I. Hsu, Youngho Seo, V. Weinberg, 2015, Advances in radiation oncology.

Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).

Christopher U. Jones, A. Kishan, M. Sydes, 2022, European urology.

Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer.

M. Cooperberg, P. Carroll, S. Behr, 2019, European urology oncology.

Radium-223: down to the bone, and less is more.

M. Roach, A. Chang, 2012, Oncology.

Erratum: Multimodality therapy in stage III non-small cell lung cancer (Ann Thorac Surg 1996;61:1564-72)

D. Gandara, M. Edelman, M. Roach, 1996 .

Radical prostatectomy v radiation: only a randomised trial can provide the answer

M. Roach, 2014, BMJ : British Medical Journal.

"Supplemental beam" and prostate brachytherapy: a simple answer to a complicated question?

M. Roach, 2003, International journal of radiation oncology, biology, physics.

Current status of androgen suppression and radiotherapy for patients with prostate cancer

M. Roach, 1999, The Journal of Steroid Biochemistry and Molecular Biology.

Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials

Jonathan E. Shoag, A. Kishan, M. Sydes, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk?

M. Roach, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level IV

A. Markoe, H. Sandler, J. Purdy, 2002 .

Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.

I. Hsu, A. Gottschalk, M. Roach, 2017, Practical radiation oncology.

Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.

I. Hsu, M. Descovich, N. Kirby, 2015, Practical Radiation Oncology.

Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery

P. Carroll, I. Hsu, V. Weinberg, 2016, American journal of clinical oncology.

Prophylactic Treatment of the Pelvic Lymphatics in Patients with High-Risk Prostate Cancer: Pro Radiation

M. Roach, 2013 .

Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.

A. Zietman, J. Moul, A. Briganti, 2012, European urology.

Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy.

J. Pouliot, I. Hsu, V. Weinberg, 2008, International journal of radiation oncology, biology, physics.

The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525.

J. Herman, M. Gilbert, M. Mehta, 2019, Neuro-oncology practice.

Comparison of intensity modulated treatment plans for multiple dominant intra-prostatic lesions of prostate cancer

P. Xia, L. Verhey, É. Vigneault, 1998 .

1007 The need for central pathology tumor grading in prostate cancer using radiation therapy oncology group(RTOG) 8531

D. Grignon, T. Pajak, G. Hanks, 1997 .

Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes

M. Meng, P. Carroll, A. Gottschalk, 2014, PloS one.

Initial Report of NRG Oncology/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate-Risk Prostatic Carcinoma

D. Beyer, C. Catton, H. Sandler, 2016 .

The Roach Equation: Value of Old Clinical Tools in the Era of New Molecular Imaging

M. Roach, Y. Li, 2020, The Journal of Nuclear Medicine.

Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).

I. Kaplan, D. Beyer, H. Sandler, 2016 .

Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14.

R. Ivker, M. Desilvio, B. Movsas, 2008, Journal of palliative medicine.

High-risk prostate cancer—classification and therapy

Howard I. Scher, Mack Roach, H. Scher, 2014, Nature Reviews Clinical Oncology.

High-risk prostate cancer: from definition to contemporary management.

M. Zelefsky, F. Montorsi, S. Boorjian, 2012, European urology.

Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials.

H. Sandler, F. Feng, D. Spratt, 2022, International journal of radiation oncology, biology, physics.

Dual fluorescent molecular substrates selectively report the activation, sustainability and reversibility of cellular PKB/Akt activity

A. Dicker, A. Pollack, M. Roach, 2022 .

Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

M. Hammond, A. Dicker, A. Pollack, 2003, Radiation oncology.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

M. Terris, A. Kishan, M. Cooperberg, 2019, JAMA oncology.

A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer.

Ronald C. Chen, A. Briganti, Liang Cheng, 2019, European urology oncology.

Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.

P. Carroll, I. Hsu, K. Shinohara, 2019, Urology.

Disease-specific survival outcomes in lymph node-positive patients with prostate cancer treated with radiotherapy.

P. Carroll, K. Shinohara, A. Gottschalk, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.

Christopher U. Jones, E. Horwitz, T. Pisansky, 2023, European urology.

Prostate‐specific antigen response after short‐term hormone therapy plus external‐beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413

I. Hsu, H. Sandler, M. Roach, 2013, Cancer.

Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.

Michael W Kattan, Mack Roach, Louis Potters, 2007, International journal of radiation oncology, biology, physics.

Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study.

P. Carroll, J. Kurhanewicz, M. Roach, 2012, International journal of radiation oncology, biology, physics.

Multimodality therapy in stage III non-small cell lung cancer.

D. Gandara, M. Edelman, M. Roach, 1996, The Annals of thoracic surgery.

Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

H. Sandler, K. Bae, W. Shipley, 2015, Cancer.

LONG‐TERM POTENCY PRESERVATION FOLLOWING BRACHYTHERAPY FOR PROSTATE CANCER

M. Roach, 2012, BJU international.

Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.

D. Grignon, H. Sandler, K. Bae, 2011, International journal of radiation oncology, biology, physics.

Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.

D. Grignon, H. Sandler, B. Donnelly, 2011, International journal of radiation oncology, biology, physics.

Influence of Number of CAG Repeats on Local Control in the RTOG 86-10 Protocol

A. Markoe, Milijenko Pilepich, E. Hammond, 2006, American journal of clinical oncology.

Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.

John H Suh, Benjamin Movsas, Charles S Cleeland, 2005, Journal of the National Cancer Institute.

Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?

L. Gaspar, M. Roach, S. Asbell, 1999, International journal of radiation oncology, biology, physics.

Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.

T. Pajak, B. Emami, J. Cox, 1993, International journal of radiation oncology, biology, physics.

Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men

Christopher U. Jones, A. Kishan, P. Boutros, 2021, JAMA network open.

Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy

D. Grignon, M. Hammond, H. Sandler, 2004, Clinical Cancer Research.

Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond

Mack Roach, M. Bucci, M. Roach, 2005, CA: a cancer journal for clinicians.

The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.

W. Sause, B. Movsas, J. Cox, 1999, International journal of radiation oncology, biology, physics.

The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets.

Ping Xia, Mack Roach, P. Xia, 2002, International journal of radiation oncology, biology, physics.

A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): preliminary analysis of RTOG 9413

Christopher U. Jones, I. Hsu, R. Valicenti, 2001 .

Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience.

Ying Lu, John Kurhanewicz, Shoujun Zhao, 2008, Radiology.

Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.

I. Hsu, J. Kurhanewicz, K. Shinohara, 2013, International journal of radiation oncology, biology, physics.

Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433.

W. Curran, R. Komaki, T. Pajak, 1993, Lung cancer.

Economic Analysis of Radiation Therapy Oncology Group 97-14: Multiple Versus Single Fraction Radiation Treatment of Patients With Bone Metastases

W. Curran, N. Janjan, M. Roach, 2009, American journal of clinical oncology.

SBRT for High-Risk Prostate Cancer

M. Descovich, A. Gottschalk, M. Anwar, 2018, Stereotactic Radiosurgery for Prostate Cancer.

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

I. Hsu, V. Weinberg, A. Gottschalk, 2013, Radiation oncology.

A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.

A. Sahgal, M. Roach, P. Cheung, 2012, International journal of radiation oncology, biology, physics.

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

A. Markoe, H. Sandler, K. Bae, 2010, International journal of radiation oncology, biology, physics.

Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level.

J. Pouliot, J. Kurhanewicz, K. Shinohara, 2006, International journal of radiation oncology, biology, physics.

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

I. Hsu, V. Weinberg, A. Gottschalk, 2014, Radiation Oncology.

Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.

I. Hsu, Lijun Ma, V. Weinberg, 2012, International journal of radiation oncology, biology, physics.

A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer.

H. Sandler, P. McLaughlin, V. Weinberg, 2003, International journal of radiation oncology, biology, physics.

Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States.

J. Blasko, J. Sylvester, P. Grimm, 2007, Brachytherapy.

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Jeff M Michalski, Mack Roach, James A Purdy, 2005, International journal of radiation oncology, biology, physics.

Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.

Richard K Valicenti, Jeff M Michalski, Mack Roach, 2004, International journal of radiation oncology, biology, physics.

Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy.

L Verhey, J Kurhanewicz, E Vigneault, 1999, International journal of radiation oncology, biology, physics.

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy

J. Pouliot, I. Hsu, Adam Cunha, 2018, Journal of contemporary brachytherapy.

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

R. Socher, James Y. Zou, M. Lungren, 2022, npj Digital Medicine.

Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.

H. Sandler, E. Horwitz, T. Pisansky, 2019, International journal of radiation oncology, biology, physics.

Reporting of results in DART01/05 GICOR.

H. Sandler, T. Pisansky, M. Roach, 2015, The Lancet. Oncology.

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

Charles R. Thomas, Mack Roach, Sucha Asbell, 2007, International journal of radiation oncology, biology, physics.

A Radiation Therapy Oncology Group experience: chemotherapy/radiation therapy of lung cancer

T. Pajak, W. Sause, C. Perez, 1993 .

Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT.

P. Xia, M. Roach, H. Chung, 2009, International journal of radiation oncology, biology, physics.

Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP)

I. Kaplan, D. Beyer, H. Sandler, 2020, International Journal of Radiation Oncology*Biology*Physics.

Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

Adam P Dicker, Richard Stock, Steven Frank, 2012, BJU international.

Endorectal MRI after radiation therapy: Questioning the sextant analysis

J. Kurhanewicz, M. Roach, C. McCulloch, 2011, Journal of magnetic resonance imaging : JMRI.

Erectile dysfunction after radiotherapy for prostate cancer: a model assesing the conflicting literature on dose–volume effects

K. Thomas, V. Weinberg, M. Roach, 2013, International Journal of Impotence Research.

Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial.

Christopher U. Jones, A. Zietman, H. Sandler, 2021, International journal of radiation oncology, biology, physics.

Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging.

J. Kurhanewicz, R. T. Ten Haken, K. Shinohara, 2004, International journal of radiation oncology, biology, physics.

Stampede to Cure.

M. Roach, Y. Li, 2019, International journal of radiation oncology, biology, physics.

Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.

Julian C. Hong, A. D'Amico, M. Cooperberg, 2023, European urology oncology.

Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy.

P. Carroll, K. Shinohara, M. Roach, 1998, The Journal of urology.

Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy.

B Pickett, P Xia, L J Verhey, 2001, International journal of radiation oncology, biology, physics.

Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy.

I. Hsu, J. Kurhanewicz, Ying Lu, 2009, International journal of radiation oncology, biology, physics.

Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.

A. Markoe, H. Sandler, J. Purdy, 2004, International journal of radiation oncology, biology, physics.

Clinical Scenario: Bladder Preservation

M. Roach, Maurice M. Garcia, A. Chang, 2015 .

Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.

David E Morris, Joel E Tepper, Mack Roach, 2005, International journal of radiation oncology, biology, physics.

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer

V. Weinberg, A. Gottschalk, M. Anwar, 2016, Radiation Oncology.

Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

P. Rubin, W. Sause, W. Shipley, 2002, International journal of radiation oncology, biology, physics.

Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx).

D. Beyer, H. Sandler, É. Vigneault, 2021, International journal of radiation oncology, biology, physics.

Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer.

L. Potters, L. Verhey, M. Steinberg, 2008, International journal of radiation oncology, biology, physics.

RADIATION THERAPY ONCOLOGY GROUP RTOG 94-13 A PHASE III TRIAL COMPARING WHOLE PELVIC IRRADIATION FOLLOWED BY A CONEDOWN BOOST TO BOOST IRRADIATION ONLY AND COMPARING NEOADJUVANT TO ADJUVANT TOTAL ANDROGEN SUPPRESSION (TAS)

M. Roach, 1999 .

Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

H. Sandler, R. Dess, R. Valicenti, 2022, Cancer.

Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.

A. Markoe, H. Sandler, J. Purdy, 2003, International journal of radiation oncology, biology, physics.

Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406.

A. Markoe, H. Sandler, J. Purdy, 2002, Seminars in radiation oncology.

Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes.

H. Hricak, J. Kurhanewicz, J. Speight, 2001, Radiology.

Stereotactic Body Radiation Therapy (SBRT)

Director, P. Sneed, J. Nakamura, 2013 .

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.

M. Kattan, L. Potters, M. Zelefsky, 2009, International journal of radiation oncology, biology, physics.

Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

P. Rubin, M. Desilvio, W. Sause, 2006, International journal of radiation oncology, biology, physics.

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.

I. Kaplan, D. Beyer, H. Sandler, 2018, International journal of radiation oncology, biology, physics.

Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer.

I. Hsu, P. Xia, J. Speight, 2008, International journal of radiation oncology, biology, physics.

High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.

I. Hsu, V. Weinberg, K. Shinohara, 2009, Brachytherapy.

Sociodemographic analysis of patients in radiation therapy oncology group clinical trials.

Srinivasan Vijayakumar, J. Cox, M. Bondy, 1998, International journal of radiation oncology, biology, physics.

Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy for Clinically Localized Prostate Cancer: How Good Is the Evidence?

M. Roach, A. Lazar, T. C. Ceron Lizarraga, 2015, International journal of radiation oncology, biology, physics.

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

D. Grignon, H. Sandler, H. Lepor, 2015, International journal of radiation oncology, biology, physics.

1127: Socio-Demographic Predictors of Biochemical Failure and Survival Among High Risk Patients Treated on Radiation Therapy Oncology Group (RTOG) Prostate Cancer Trials: A Meta-Analysis

B. Movsas, J. Cox, G. Hanks, 2006 .

Is it time to change the standard of care from CT to MRI for defining the apex of the prostate to accomplish potency-sparing radiotherapy?

M. Roach, 2005, International journal of radiation oncology, biology, physics.

Effect of adjuvant radiation therapy on urodynamic parameters following radical retropubic prostatectomy

C. Kane, P. Narayan, M. Roach, 1996 .

Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

A. Dicker, A. Pollack, M. Roach, 2013, Radiation Oncology.

Long-term results of NRG Oncology/RTOG 0321 a phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate.

I. Hsu, G. Gustafson, H. Sandler, 2019, International journal of radiation oncology, biology, physics.

Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing".

M. Roach, 2003, International journal of radiation oncology, biology, physics.

Phase III randomized trial of 8 Gy in 1 fraction vs. 30 Gy in 10 fractions for palliation of painful bone metastases: preliminary results of RTOG 97-14

B. Movsas, M. Roach, J. Suh, 2003 .

Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines.

Oliver Sartor, Richard K Valicenti, Mack Roach, 2013, International journal of radiation oncology, biology, physics.

Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.

I. Hsu, H. Sandler, P. McLaughlin, 2010, International journal of radiation oncology, biology, physics.

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer

V. Weinberg, A. Gottschalk, M. Anwar, 2016, Radiation oncology.

Title Duration of Androgen Deprivation in Locally Advanced Prostate Cancer : Long-Term

D. Grignon, H. Lepor, T. Pisansky, 2017 .

Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.

I. Hsu, V. Weinberg, K. Shinohara, 2005, Brachytherapy.

Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.

M. Roach, R. Byhardt, C. Scott, 1999, International journal of radiation oncology, biology, physics.

Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 9714

M. Desilvio, B. Movsas, M. Roach, 2004 .

Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.

I. Hsu, J. Cunha, K. Shinohara, 2015, Brachytherapy.

Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology.

John Kurhanewicz, Mekhail Anwar, Mack Roach, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Age dramatically impacts on the quality-adjusted time without symptoms or toxicity (Q-Twist) in locally advanced non-Small cell lung cancer (LA-NSCLC)-a radiation therapy oncology group (RTOG) analysis

R. Komaki, W. Sause, B. Movsas, 2000 .

Pre-plan parameters predict post-implant D90 ≥ 140 Gy for 125I permanent prostate implants

V. Weinberg, K. Shinohara, A. Gottschalk, 2014, Journal of contemporary brachytherapy.

Flutamide-induced liver toxicity including fatal hepatic necrosis.

K. Fu, M. Roach, J. Holland, 1996, International journal of radiation oncology, biology, physics.

FLUTA~~E-rNDUCED LIVER TOXICITY INCLUDING FATAL MEPATIC NECROSIS

K. Fu, M. Roach, J. Holland, 1995 .

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities

I. Hsu, E. Horwitz, D. D'Souza, 2018, Advances in radiation oncology.

Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer

I. Kaplan, D. Beyer, H. Sandler, 2016 .

Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable.

M. Kattan, L. Potters, M. Zelefsky, 2010, International journal of radiation oncology, biology, physics.

Phase I II T rial C omparing W hole-Pelvic V ersus P rostate-Only Radiotherapy a nd N eoadjuvant V ersus A djuvant C ombined Androgen S uppression: R adiation T herapy O ncology Group 9 413

C. Jones, M. Desilvio, M. Roach, 2003 .

ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate.

P. Carroll, G. Merrick, D. Beyer, 2009, International journal of radiation oncology, biology, physics.

High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes.

I. Hsu, V. Weinberg, K. Shinohara, 2008, International journal of radiation oncology, biology, physics.

Technique for Implantation of Fiducial Markers in the Prostate

K. Shinohara, M. Roach, 2007 .

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.

D. Beyer, C. Catton, H. Sandler, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1011 Dose to the bulb of the penis is associated with the risk of impotence following radiotherapy for prostate cancer

V. Weinberg, B. Fisch, B. Pickett, 1999 .

Patterns of Local Failure following Radiation Therapy for Prostate Cancer.

Kirsten L. Greene, P. Carroll, K. Shinohara, 2015, The Journal of urology.

Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.

M. Roach, B. Gartrell, G. Priore, 2019, Journal of Clinical Oncology.

Typical hormone deprivation side effects compared to SM-88 therapy for rising PSA.

M. Roach, B. Gartrell, G. Priore, 2019, Journal of Clinical Oncology.

Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.

M. Roach, G. Priore, G. Sokol, 2018 .

Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer

H. Scher, M. Roach, B. Gartrell, 2017, Annals of Oncology.

Postoperative radiation therapy for patients at high‐risk of recurrence after radical prostatectomy: does timing matter?

M. Cooperberg, P. Carroll, M. Roach, 2015, BJU international.

Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the Stephenson nomogram.

P. Span, J. Witjes, J. Barentsz, 2012, International journal of radiation oncology, biology, physics.

Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward.

M. Roach, O. Kaidar-Person, G. Créhange, 2013, International journal of radiation oncology, biology, physics.

Interruptions of high-dose radiation therapy for non-small cell carcinoma of the lung decrease long-term survival in favorable patients

T. Pajak, B. Emami, J. Cox, 1992 .

Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes

M. Meng, P. Carroll, A. Gottschalk, 2016, PLoS ONE.

An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation

M. Descovich, A. Gottschalk, M. Roach, 2017, Technology in cancer research & treatment.

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials.

D. Grignon, M. Roach, M. Mohiuddin, 2000, International journal of radiation oncology, biology, physics.

Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.

T L Phillips, P Xia, P. Xia, 2001, Urology.

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

R K Valicenti, M Machtay, C. Jones, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation Therapy Oncology Group (RTOG) 9408: A Secondary Analysis of the Risk of Death From Second Cancers Comparing Whole Pelvic (WP) Radiation Therapy (RT) to Prostate Only (PO) RT and Neoadjuvant Hormonal Therapy (NHT) + RT to RT Alone

Christopher U. Jones, H. Sandler, M. Roach, 2013 .

Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis

I. Hsu, Adam Cunha, A. Sudhyadhom, 2021, International Journal of Radiation Oncology*Biology*Physics.

Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer

A. Sudhyadhom, M. Descovich, Josephine Chen, 2017, Technology in cancer research & treatment.

Commentary on increased risk of biochemical and local failure in patients with a distended rectum on the planning CT for prostate cancer radiotherapy.

Mack Roach, M. Roach, 2005, International journal of radiation oncology, biology, physics.

Potency following high-dose three-dimensional conformal radiotherapy and the impact of prior major urologic surgical procedures in patients treated for prostate cancer.

M. Roach, M. Roach, J. Holland, 1995, International journal of radiation oncology, biology, physics.

Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy.

P. Carroll, K. Shinohara, M. Roach, 2000, Urology.

Early Salvage Radiotherapy Following Radical Prostatectomy

M. Zelefsky, T. Wiegel, A. Briganti, 2014 .

Management of a positive surgical margin after radical prostatectomy: decision analysis.

P. Carroll, V. Weinberg, M. Roach, 2000, The Journal of urology.

Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns.

P. Carroll, V. Weinberg, M. Roach, 1999, Urology.

Salvage high dose rate brachytherapy for recurrent prostate cancer after definitive radiation.

I. Hsu, J. Cunha, G. Valdes, 2021, Practical radiation oncology.

Imaging and radiotherapy of the prostate.

J. Speight, M. Roach, M. Roach, 2000, Radiologic clinics of North America.

Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541.

D. Berry, M. Roach, D. Hayes, 1997, The cancer journal from Scientific American.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

M. Hammond, H. Sandler, M. Desilvio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward.

M. Roach, O. Kaidar-Person, G. Créhange, 2013, International journal of radiation oncology, biology, physics.

High-risk prostate cancer: from definition to contemporary management.

M. Zelefsky, F. Montorsi, S. Boorjian, 2012, European urology.

“High-Risk” Prostate Cancer: Classification and Therapy

M. Roach, A. Chang, K. Autio, 2015 .

Economic Analysis of Radiation Therapy Oncology Group 97-14: Multiple Versus Single Fraction Radiation Treatment of Patients With Bone Metastases

W. Curran, N. Janjan, M. Roach, 2009, American journal of clinical oncology.

Five-year patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer.

I. Kaplan, H. Sandler, E. Horwitz, 2022, International journal of radiation oncology, biology, physics.

Functional interference clusters in cancer patients with bone metastases: a secondary analysis of RTOG 9714.

S. Ratcliffe, R. Ivker, A. Barsevick, 2008, International journal of radiation oncology, biology, physics.

I. Hsu, H. Sandler, V. Weinberg, 2010, International journal of radiation oncology, biology, physics.

Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy.

I. Hsu, M. Roach, D. Raleigh, 2015, Brachytherapy.